Critical evaluation of the role of acarbose in the treatment of diabetes: Patient considerations

Diabetes, Metabolic Syndrome and Obesity

Volumn 5, Issue , 2012, Pages 357-367

  Rosak, Christoph ^a   Mertes, Gabriele ^b  

^a Sachsenhausen Hospital   (Germany)

^b NONE

Author keywords

Acarbose; Patient considerations; Prediabetes; Side effects; Type 2 diabetes

Indexed keywords

ACARBOSE; AMINOTRANSFERASE; ANTIDIABETIC AGENT; DIURETIC AGENT; GLINIDE DERIVATIVE; GLIPTINE DERIVATIVE; GLITAZONE DERIVATIVE; GLUCAGON; GLUTIDE DERIVATIVE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG; VILDAGLIPTIN;

ABDOMINAL DISCOMFORT; ARTHRITIS; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; DIABETES CONTROL; DIABETES MELLITUS; DIABETIC PATIENT; DIARRHEA; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; EDEMA; FLATULENCE; FRACTURE; GASTROINTESTINAL TOXICITY; GLUCONEOGENESIS; HEART ARRHYTHMIA; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INFECTION; INFLAMMATION; INSULIN RELEASE; INSULIN RESISTANCE; LOW DRUG DOSE; METEORISM; MONOTHERAPY; MORBIDITY; MORTALITY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREATITIS; PATIENT COMPLIANCE; PLEIOTROPY; POSTPRANDIAL STATE; RESPIRATORY TRACT INFECTION; RETINA MACULA EDEMA; REVIEW; SIDE EFFECT; TREATMENT DURATION; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 84872311972     PISSN: 11787007     EISSN: None     Source Type: Journal    
DOI: 10.2147/dmso.s28340     Document Type: Review

References (108)

1. International Diabetes Federation. IDF Diabetes Atlas, 5th ed. Brussels, Belgium: International Diabetes Federation, 2011. Available from: http://www.idf.org/diabetesatlas. Accessed May 16, 2012.
2. The DECODE Study Group. Glucose tolerance and cardiovascular mortality. Arch Intern Med. 2001;161:397-404.
3. Bischoff H. Effect of acarbose on diabetic late complications and risk factors - new animal experimental results. Akt Endokr Stoffw. 1991;12:25-32.
4. Elsenhans B, Caspary WF. Absorption of carbohydrates. In: Caspary WF, editor. Structure and Function of the Small Intestine. Amsterdam, The Netherlands: Excerpta Medica; 1987.
5. Puls W. Pharmacology of glucosidase inhibitors. In: Kuhlmann J, Puls W, editors. Handbook of Experimental Pharmacology: Oral Antidiabetics. Volume 119. Berlin, Germany: Springer; 1996.
6. Bischoff H. Alpha-glucosidase inhibition, a new therapeutic principle in the management of diabetes mellitus. In: Schwartz CJ, Born GVR, editors. New Horizons in Diabetes Mellitus and Cardiovascular Disease. London, UK: Current Science; 1995.
7. Rosak C, Mertes G. Effects of acarbose on proinsulin and insulin secretion and their potential significance for the intermediary metabolism and cardiovascular system. Curr Diabetes Rev. 2009;5:157-164.
8. Alessema M, Dekker JM, Nijpels G, Stehouwer CDA, Bouter LM, Heine RJ. Proinsulin concentration is an independent predictor of all-cause and cardiovascular mortality: an 11-year follow-up of the Hoorn Study. Diabetes Care. 2005;28:860-865.
9. Qualmann C, Nauck MA, Holst JJ, Orskov C, Creutzfeldt W. Glucagon-like peptide 1 (GLP-1) [17-36 amide] secretion in response to luminal sucrose from the upper and lower gut: a study using alpha-glucosidase inhibition (acarbose). Scand J Gastroenterol. 1995;30:892-896.
10. Göke B, Fuder H, Wieckhorst G, et al Voglibose is an efficient alpha-glucosidase inhibitor and mobilizes the endogenous GLP-1 reserve. Digestion. 1995;56:493-501.
11. Hanefeld M, Temelkowa-Kurktschiev T. The postprandial state and the risk of atherosclerosis. Diab Med. 1997;14:S6-S11.
12. Barrett-Connor E, Ferrara A. Isolated postprandial hyperglycemia and the risk of fatal cardiovascular disease in older woman and men. The Rancho Bernardo Study. Diabetes. 1998;21:1236-1240.
13. de Vegt F, Dekker JM, Ruhè HG, Stehouwer CDA, Nijpels GBLM, Heine RJ. Hyperglycemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia. 1999;42:926-931.
14. Giugliano D, Marfella R, Coppola L, etal Vascular effects of acute hyperglycemia in humans are reversed by L-arginine. Evidence for reduced availability of nitric oxide during hyperglycemia. Circulation. 1997;95:1783-1790.
15. Kawano H, Motoyama T, Hirashima O, etal Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol. 1999;34:146-154.
16. Ceriello A, Falleti E, Motz E, etal. Hyperglycemia-induced circulating ICAM-1increase in diabetes mellitus: the possible role of oxidative stress. Horm Metab Res. 1998;30:146-149.
17. Marfella R, Esposito K, Giunta R, etal. Circulating adhesion molecules in humans: role of hyperglycemia and hyperinsulinemia. Circulation. 2000;101:2247-2251.
18. Esposito K, Nappo F, Marfella R, etal. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation. 2002;106:2067-2072.
19. Festa A, D'Agostino R Jr, Tracy RP, Haffner SM. C-reactive protein is more strongly related to post-glucose load glucose than to fasting glucose in non-diabetic subjects; the Insulin Resistance Atherosclerosis Study. Diab Med. 2002;19:939-943.
20. Shimabukuro M, Higa N, Chinen I, Yamakawa K, Takasu N. Effects of a single administration of acarbose on postprandial glucose excursion and endothelial dysfunction in type 2 diabetic patients: a randomized crossover study. J Clin Endocrinol Metab. 2006;91:837-842.
21. Wascher TC, Schmoelzer I, Wiegratz A, etal. Reduction of postchallenge hyperglycemia prevents acute endothelial dysfunction in subjects with impaired glucose tolerance. Eur J Clin Invest. 2005;35:551-557.
22. Kato T, Inoue T, Node K. Postprandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative study. Cardiovasc Diabetol. 2010;9:12-16.
23. Hanefeld M, Chiasson JL, Koehler C, Henkel E, Schaper F, Temelkova-Kurktschiev T. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke. 2004;35:1073-1078.
24. Rosenthal JH, Mauersberger H. Effects on blood pressure of the alpha-glucosidase-inhibitor acarbose compared with the insulin enhancer glibenclamide in patients with hypertension and type 2 diabetes mellitus. Clin Drug Investig. 2002;22:695-701.
25. Hanefeld M, Catagay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J. 2004; 25:10-16.
26. Wang X, Lu J, Pan C. Comparison of serum C-reactive protein level in different glucose tolerant subjects and the change in serum CRP level in IGT subjects with acarbose. Chin J Endocrinol Metab. 2003;19: 254-256.
27. Rudofski G, Reismann P, Schiekofer S. Reduction of postprandial hyperglycemia in patients with Type 2 diabetes reduces NF-kappaB activation in PBMCs. Horm Metab Res. 2004;36:630-638.
28. Baron AD, Eckel RH, Schmeiser L, Kolterman OG. The effect of short-term alpha-glucosidase inhibition on carbohydrate and lipid metabolism in type II diabetics. Metabolism. 1987;36:409-415.
29. Kado S, Murakami T, Aoki A, etal Effect of acarbose on postprandial lipid metabolism in type 2 diabetes mellitus. Diab Res Clin Pract. 1998; 41:49-55.
30. Malaguarnera M, Giugno I, Ruello P, Rizzo M, Motto M, Mazzoleni G. Acarbose is an effective adjunct to dietary therapy in the treatment of hypertriglyceridemias. Br J Clin Pharmacol. 1999;48:605-609.
31. Ogawa S, Takeuchi K, Ito S. Acarbose lowers serum triglyceride and postprandial chylomicron levels in type 2 diabetes. Diab Obes Metab. 2004;6:384-390.
32. Tushuizen ME, Diamant M, Heine RJ. Postprandial dysmetabolism and cardiovascular disease in type 2 diabetes. Postgrad Med J. 2005;81:1-6.
33. Ceriello A, Taboga C, Tonutti L, etal Post-meal coagulation activation in diabetes mellitus: the effect of acarbose. Diabetologia. 1996;39: 469-473.
34. Tschoepe D. Decreased fibrinogen by treatment with the alpha-glucosidase inhibitor acarbose. Diabetes. 2004;53 Suppl 2:A189.
35. Shinoda Y, Inoue I, Nakano T, etal. Acarbose improves fibrinolytic activity in patients with impaired glucose tolerance. Metabolism. 2006; 55:935-939.
36. Rathmann W, Giani G, Mielck A. Cardiovascular risk factors in newly diagnosed abnormal glucose tolerance: comparison of 1997ADA and WHO criteria. Diabetologia. 1999;42:1268-1269.
37. Coutinho M, Gerstein HC, Wang Y, Yussuf S. The relationship between glucose and incident cardiovascular events: a metaregression analysis of published data from 20studies of 95,783individuals followed for 12.4 years. Diabetes Care. 1999;22:233-240.
38. Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes. 1999;48:937-942.
39. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;359:2072-2077.
40. Chiasson J-L, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance. The STOP-NIDDM Trial. JAMA. 2003;290:486-494.
41. Hanefeld M, Pistrosch F, Koehler C, Chiasson JL. Conversion of IGT to type 2 diabetes mellitus is associated with incident cases of hypertension: a post-hoc analysis of the STOP-NIDDM trial. J Hypertens. 2012;30:1440-1443.
42. Acarbose Cardiovascular Evaluation (ACE study). Available from: http://www.dtu.ox.ac.uk/ace/. Accessed June 19, 2012.
43. Coniff RF, Shapiro JA, Seaton TB, Bray GA. Multicenter, placebo-controlled trial comparing acarbose (Bay g 5421) with placebo, tolbutamide and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. Am J Med. 1995;98:443-451.
44. Rosak C, Haupt E, Walter T, Werner J. The effect of combination treatment with acarbose and glibenclamide on postprandial glucose and insulin profiles: additive blood glucose lowering effect and decreased hypoglycaemia. Diabetes Nutr Metab. 2002;15:143-151.
45. Phung OJ, Scholle JM, Talwar M, Coleman CI. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA. 2010;303: 1410-1418.
46. Lin SD, Wang JS, Hsu SR, etal. The beneficial effect of α-glucosidase inhibitor on glucose variability compared with sulfonylurea in Taiwanese type 2 diabetic patients inadequately controlled with metformin: preliminary data. J Diabetes Complications. 2011;25:332-338.
47. Tschöpe D, Bramlage P, Binz C, etal. Antidiabetic pharmacotherapy and anamnestic hypoglycemia in a large cohort of type 2 diabetic patients - an analysis of the DiaRegis registry. Cardiovasc Diabetol. 2011;10:66.
48. van de Laar FA, Lucassen PL, Akkermans LP, van de Lisdonk EH, Rutten GE, van Weel C. Alpha-glucosidase inhibitors for patients with type 2 diabetes. Results from a Cochrane systematic review and meta-analysis. Diabetes Care. 2005;28:154-163.
49. Bolen S, Feldmann L, Vassy J, etal. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med. 2007;147:386-399.
50. Schnell O, Mertes G, Standl E, On behalf of the Acarbose-Insulin Combination Study Group. Acarbose and metabolic control in patients with type 2 diabetes with newly initiated insulin therapy. Diabetes Obes Metab. 2007;9:853-888.
51. Li C, Hung YJ, Quamruddin K, Aziz MFA, Stein H, Schmidt B. International noninterventional study of acarbose treatment in patients with type 2 diabetes mellitus. Diab Res Clin Pract. 2011;92: 57-64.
52. Willms B, Ruge D. Comparison of acarbose and metformin in patients with type 2 diabetes mellitus insufficiently controlled with diet and sulphonylureas: a randomized, placebo-controlled study. Diabet Med. 1999;16:755-761.
53. Pan C, Yang W, Barona JP, etal. Comparison of vildagliptin and acarbose monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabet Med. 2008;25:435-441.
54. Home PD, Pocock SJ, Beck-Nielsen H, etal. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009;373:2125-2135.
55. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352: 854-865.
56. Holman RR, Turner RC, Cull CA, On behalf of the UKPDS Study Group. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (UKPDS 44). Diabetes Care. 1999;22:960-964.
57. Fischer S, Hanefeld M, Spengler M, Boehme K, Temelkowa-Kurktschiev T. European study on dose-response relationship of acarbose as a first-line drug in non-insulin-dependent diabetes mellitus. Acta Diabetol. 1998;35:34-40.
58. Hasche H, Mertes G, Bruns C, etal. Effects of acarbose treatment in type 2 diabetic patients under dietary training: a multicenter, double-blind, placebo-controlled, 2-year study. Diabetes Nutr Metab. 1999;12: 277-285.
59. Mertes G. Safety and efficacy of acarbose in the treatment of type 2 diabetes: data from a 5-year surveillance study. Diabetes Res Clin Pract. 2001;52:193-204.
60. Brauer PM, Slavin JL, Marlett JA. Apparent digestibility of neutral detergent fiber in elderly and young adults. Am J Clin Nutr. 1981;34: 1061-1070.
61. Bowman B, Rosenberg IH. Digestive function and aging. Hum Nutr Clin Nutr. 1983;37C:75-89.
62. Welsh JD, Poley JR, Bhatia M, Stevenson DE. Intestinal disaccharidase activities in relation to age, race and mucosal damage. Gastroenterology. 1978;75:847-855.
63. Buse J, Hart K, Minasi LA, on behalf of the PROTECT Study Group. The PROTECT study: Final results of a large multicenter postmarketing study in patients with type 2 diabetes. Clin Ther. 1998;20:257-269.
64. Spengler M, Schmitz H, Landen H. Evaluation of the efficacy and tolerability of acarbose in patients with diabetes mellitus - a postmarketing surveillance study. Clin Drug Investig. 2005;25:651-659.
65. Pan CY, Landen H. Post-marketing surveillance of acarbose treatment in patients with type 2 diabetes mellitus and subjects with IGT in China. Clin Drug Investig. 2007;27:397-405.
66. Santeusiano F, Ventura MM, Contadini S, etal Efficacy and safety of two different dosages of acarbose in non-insulin dependent diabetic patients treated by dietalone. Diabetes Nutr Metab. 1993;6:147-154.
67. Radziuk J, Kemmer F, Morishima T, Berchtold P, Vranic M. The effects of an alpha-glucosidase hydrolase inhibitor on glycemia and the absorption of sucrose in man determined using a tracer method. Diabetes. 1984;33:207-213.
68. May C. Wirksamkeit und Verträglichkeit von einschleichend dosierter Acarbose bei Patienten mit nichtinsulinpflichtigem Diabetes mellitus unter Sulfonylharnstofftherapie. Diabetes Stoffwechsel. 1995;4:3-8. German.
69. Creutzfeldt W, Fölsch UR, Elsenhaus B, Ballmann M, Conlon M. Adaptation of the small intestine to induced maldigestion. Scand J Gastroenterol. 1985;20:45-53.
70. Koytchev R, Richter W, Erkent U, etal. Influence of acarbose on blood glucose and breath hydrogen after carbohydrate load with sucrose or starch. Arzneimittelforschung. 2009;59:557-563.
71. Sherifali D, Nerenberg K, Pullenayegum E, Cheng JE, Gerstein HC. The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis. Diabetes Care. 2010;33:1859-1864.
72. Ashcroft FM. Mechanism of the glycemic effects of sulfonylureas. Horm Metab Res. 1996;28:456-463.
73. Panten U, Schwanstecher M, Schwanstecher C. Sulfonylurea receptors and mechanism of sulfonylurea action. Exp Clin Endocrinol Diabetes. 1996;104:1-9.
74. Bijlstra PJ, Luttermann JA, Russel FGM, Thien T, Smits P. Interaction of sulphonylurea derivatives with vascular ATP-sensitive potassium channels in humans. Diabetologia. 1996;39:1083-1090.
75. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
76. Giovannucci E, Harlan DM, Archer MC, etal. Diabetes and cancer: A consensus report. Diabetes Care. 2010;33:1674-1685.
77. Guay DRP. Repaglinide, a novel short-acting hypoglycemic agent for type 2 diabetes mellitus. Pharmacotherapy. 1998;18:1195-1204.
78. Marbury T, Huang WC, Strange P, Lobovitz H. Repaglinide versus glyburide: a one year comparison trial. Diab Res Clin Pract. 1999;43: 155-165.
79. Bloomgarden ZT. Metformin. Diabetes Care. 1995;18:1078-1092.
80. Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996;334:574-579.
81. Li CL, Pan CY, Lu JM, etal. Effect of metformin on patients with impaired glucose tolerance. Diabet Med. 1999;16:477-481.
82. Yang W, Lin L, Qi J, etal. The preventive effect of acarbose and metformin on the progression to diabetes mellitus in the IGT population: a 3-year multicenter prospective study. Chin J Endocrinol Metab. 2001;17:131-136.
83. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007; 356:2457-2471.
84. Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, etal Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA. 2010;304:411-418.
85. Wertz DA, Chang CL, Sarawate CA, Willey VJ, Cziraky MJ, Bohn RL. Risk of cardiovascular events and all-cause mortality in patients treated with thiazolidinediones in a managed-care population. Circ Cardiovasc Qual Outcomes. 2010;3:538-545.
86. Loke YK, Kwok CS, Singh S. Comparative cardiovascular effects of thiazolidinediones: systematic review and metaanalysis of observational studies. BMJ. 2011;342:d1309.
87. Kahn SE, Zinman B, Lachin JM, etal. Rosiglitazone-associated fractures in type 2 diabetes. Diabetes Care. 2008;31:845-851.
88. Dormuth CR, Carney G, Carleton B, Bassett K, Wright JM. Thiazolidindiones and fractures in men and women. Arch Intern Med. 2009;169: 1395-1402.
89. Idris I, Warren G, Donnelly R. Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes. Arch Intern Med. June 11, 2012. [Epub ahead of print.]
90. Piccinni C, Motola D, Marchesini G, Poluzzi E. Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care. 2011;34:1369-1371.
91. Kahn SE, Haffner SM, Heise MA, etal. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2008;355:2427-2443.
92. Ryan KK, Li B, Grayson BE, Matter EK, Woods SC, Seeeley RJ. A role for central nervous system PPAR-γ in the regulation of energy balance. Nat Med. 2011;17:623-626.
93. Cure P, Pileggi A, Alejandro R. Exenatide and adverse events. N Engl J Med. 2008;358:1969-1970.
94. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes. Systematic review and metaanalysis. JAMA. 2007; 298:194-206.
95. Williams-Herman D, Engel SS, Round E, etal. Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr Disord. 2010;10:7-11.
96. Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch C. Emerging role of dipeptidyl peptidase-4inhibitors in the management of type 2 diabetes. Vasc Health Risk Manag. 2008;4:753-768.
97. Tripathy NR, Basha S, Jain R, Shetty S, Ramachandran A. Exenatide and acute pancreatitis. J Assoc Physicians India. 2008;56:987-988.
98. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011;141:150-156.
99. Drucker DJ, Sherman SI, Gorelick FS, Bergenstal RM, Sherwin RS, Buse JB. Incretin-based therapies for the treatment of type 2 diabetes: Evaluation of the risks and benefits. Diabetes Care. 2010;33: 428-433.
100. Salvatore T, Giugliano D. Pharmacokinetic-pharmacodynamic relationships of acarbose. Clin Pharmacokinet. 1996;30:94-106.
101. Ahr HJ, Krause HP, Siefert HM, Steinke W, Weber H. Pharmacokinetics of acarbose, Part II: Distribution to and elimination from tissues and organs following single or repeated administration of [14C] acarbose to rats, dogs and man. Arzneimittelforschung. 1989;39:1261-1267.
102. Coniff RF, Krol A. Acarbose: a review of US clinical experience. Clin Ther. 1997;19:16-26.
103. Lebovitz HE. Alpha-glucosidase-inhibitors as agents in the treatment of type 2 diabetes. Diabetes Reviews. 1998;6:132-145.
104. Haupt E, Hillebrand I, Pfeiffer H. Effectiveness and tolerability of the alpha-glucosidase-inhibitor acarbose in NIDDM patients with elevated liver enzyme activity. In: Creutzfeldt W, editor. Acarbose for the Treatment of Diabetes Mellitus. Berlin, Germany: Springer Verlag; 1988.
105. Zillikens MC, Swart GR, van den Berg JWO, Wilson JHP. Effects of the glucosidase-inhibitor acarbose in patients with liver cirrhosis. Aliment Pharmacol Ther. 1989;3:453-459.
106. Kihara Y, Ogami Y, Tabaru A, Unoki H, Otsuki M. Safe and effective treatment of diabetes mellitus associated with chronic liver diseases with an alpha-glucosidase-inhibitor, acarbose. Gastroenterology. 1997;6:777-782.
107. Rao AD, Reynolds K, Kuhadiya N, Fonsera VA. Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality? A meta-analysis. Diabetes Care. 2008;31:1672-1678.
108. Rosak C, Nitzsche G, Konig P, Hofmann U. The effect of timing and the administration of acarbose on postprandial hyperglycemia. Diab Med. 1995;12:979-984.